Autoantibodies to pancreatic hsp60 precede the development of glucose intolerance in patients with cystic fibrosis.
Persons expressing the genetic disease cystic fibrosis (CF) suffer from a high risk of developing impaired glucose tolerance and diabetes. The development of diabetes in CF has been attributed, in the past, to the destruction of pancreatic islets and their resident beta-cells secondary to the destruction of the surrounding tissue by mechanical clogging of the pancreatic exocrine ducts. However, the discovery that autoimmunity to the 60-kDa heat shock protein (hsp60) may cause type I diabetes in NOD mice raises the possibility that hsp60 autoimmunity may be involved in CF diabetes too; could the hyperimmunization to bacterial hsp60 characteristic of CF spread to self-hsp60 and hence to autoimmune diabetes? We now report that rising levels of IgG autoantibodies to hsp60 do indeed precede the appearance of glucose intolerance and diabetes in CF patients. We produced a recombinant human pancreatic hsp60 protein and investigated the IgG antibody response to hsp60 in prediabetic and non-diabetic patients with CF. To detect hsp60 autoantibodies in the presence of high levels of antibodies to bacterial hsp60, we absorbed test sera with the 60-kDa GroEL of Pseudomonas aeruginosa and used an immunostaining technique. Using this technique, 32 prediabetic CF patients were evaluated over a five-year period, three years, on the average, before the onset of glucose intolerance. We found that a significant increase in hsp60 autoantibody preceded impaired glucose tolerance (P=0.042, n=17), diabetes (P=0.011, n=15) and glucose intolerance (P=0.005, n=32). As has been observed in NOD mice and in type I diabetic patients, the hsp60 autoantibodies decline at the outbreak of glucose intolerance in the CF patients. The association of CF diabetes with the rise and fall of hsp60 autoimmunity suggests that the pathogenesis of the diabetes may not be merely mechanical, but arise in the wake of bacterial hyperimmunisation.
Jensen
P
P
Department of Clinical Microbiology and The Danish Cystic Fibrosis Centre, Department of Paediatrics, National University Hospital, Copenhagen, Denmark. pej@biobase.dk
Johansen
H K
HK
Carmi
P
P
Høiby
N
N
Cohen
I R
IR
D000293:Adolescent; D000328:Adult; D001323:Autoantibodies / Q000096:biosynthesis*; D018834:Chaperonin 60 / Q000276:immunology*; D003550:Cystic Fibrosis / Q000209:etiology / Q000276:immunology*; D003920:Diabetes Mellitus / Q000209:etiology / Q000276:immunology; D005260:Female; D018149:Glucose Intolerance / Q000209:etiology / Q000276:immunology*; D006801:Humans; D008137:Longitudinal Studies; D008297:Male; D010179:Pancreas / Q000276:immunology*
D001323:Autoantibodies; D018834:Chaperonin 60